GRITSTONE BIO, INC.

(GRTS)
  Report
Delayed Nasdaq  -  04:00 2022-08-08 pm EDT
3.450 USD   +0.58%
08/04GRITSTONE BIO : Reports Second Quarter 2022 Financial Results and Provides Business Update - Form 8-K
PU
08/04GRITSTONE BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
08/04Earnings Flash (GRTS) GRITSTONE BIO Reports Q2 Revenue $5.5M
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07/05/2022 | 08:01am EDT

EMERYVILLE, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors has granted eight employees nonqualified stock options to purchase an aggregate of 67,550 shares of its common stock with an exercise price of $2.66, which is equal to the closing price of Gritstone’s common stock on June 23, 2022, the grant date of the awards. These stock grants are part of an inducement material to each of the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options will vest over a four-year period, with 25% of the options vesting on the first anniversary of the employees’ date of hire, and 1/48th of the options vesting monthly thereafter, subject to the employees’ continued employment with Gritstone on such vesting dates. The options are subject to the terms and conditions of Gritstone’s 2021 Employment Inducement Incentive Award Plan and the stock option agreement covering the grant.

About Gritstone
Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product candidates to treat and prevent viral diseases and solid tumors in pursuit of improving patient outcomes and eliminating disease. www.gritstonebio.com

Gritstone Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the potential of Gritstone’s therapeutic programs; the advancements in Gritstone’s ongoing clinical trials; the timing of data announcements related to ongoing clinical trials and the initiation of future clinical trials. Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstone’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Gritstone’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Gritstone’s ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Gritstone undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gritstone in general, see Gritstone’s most recent Quarterly Report on Form 10-Q filed on May 5, 2022 and Gritstone’s future reports to be filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Gritstone as of the date hereof. Gritstone disclaims any obligation to update any forward-looking statements, except as required by law.

Gritstone Contacts
Investors:
George E. MacDougall
Director, Investor Relations & Corp Comms
Gritstone bio, Inc.
ir@gritstone.com

Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com


Primary Logo

Source: Gritstone bio

2022 GlobeNewswire, Inc., source Press Releases

All news about GRITSTONE BIO, INC.
08/04GRITSTONE BIO : Reports Second Quarter 2022 Financial Results and Provides Business Update..
PU
08/04GRITSTONE BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
AQ
08/04Earnings Flash (GRTS) GRITSTONE BIO Reports Q2 Revenue $5.5M
MT
08/04TRANSCRIPT : Gritstone bio, Inc., Q2 2022 Earnings Call, Aug 04, 2022
CI
08/04Gritstone Reports Second Quarter 2022 Financial Results and Provides Business Update
AQ
08/04Gritstone bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ende..
CI
07/26Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
07/22GRITSTONE BIO, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Fin..
AQ
07/21Gritstone to Report Second Quarter 2022 Financial Results and Provide Corporate Update ..
AQ
07/21Gritstone Establishes Credit Facility for Up to $80 Million with Hercules Capital and S..
AQ
More news
Analyst Recommendations on GRITSTONE BIO, INC.
More recommendations
Financials (USD)
Sales 2022 19,2 M - -
Net income 2022 -123 M - -
Net cash 2022 23,0 M - -
P/E ratio 2022 -2,23x
Yield 2022 -
Capitalization 252 M 252 M -
EV / Sales 2022 11,9x
EV / Sales 2023 18,2x
Nbr of Employees 193
Free-Float 97,0%
Chart GRITSTONE BIO, INC.
Duration : Period :
Gritstone bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GRITSTONE BIO, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 3,45 $
Average target price 16,00 $
Spread / Average Target 364%
EPS Revisions
Managers and Directors
Andrew R. Allen President, Chief Executive Officer & Director
Vassiliki Celia Economides Chief Financial Officer & Executive Vice President
Elaine V. Jones Chairman
Karin Jooss Head-Research & Development
Erin E. Jones Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
GRITSTONE BIO, INC.-73.17%252
CSL LIMITED1.69%99 686
SAMSUNG BIOLOGICS CO.,LTD.-0.33%49 292
WUXI BIOLOGICS (CAYMAN) INC.-20.10%40 173
BIOGEN INC.-9.05%31 571
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-22.19%22 977